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Abstract
In order to determine the feasibility of utilizing novel rexinoids for chemothera-
peutics and as potential treatments for neurological conditions, we undertook an
assessment of the side effect profile of select rexinoid X receptor (RXR) analogs
that we reported previously. We assessed pharmacokinetic profiles, lipid and thy-
roid-stimulating hormone (TSH) levels in rats, and cell culture activity of rexi-
noids in sterol regulatory element-binding protein (SREBP) induction and thyroid
hormone inhibition assays. We also performed RNA sequencing of the brain tis-
sues of rats that had been dosed with the compounds. We show here for the first
time that potent rexinoid activity can be uncoupled from drastic lipid changes
and thyroid axis variations, and we propose that rexinoids can be developed with
improved side effect profiles than the parent compound, bexarotene (1).
Abbreviation
a-beta, amyloid beta; AD, activation domain; AD, Alzheimer’s disease; AUC, area
under the curve; GFP, green fluorescent protein; HDL, high-density lipoprotein;
HRE, hormone-responsive element; LBD, ligand-binding domain; LBP, ligand-bind-
ing pocket; LDL, low-density lipoprotein; LXR, liver X receptor; PD, Parkinson’s
disease; PPAR, peroxisome proliferator-activated receptor; RAR, retinoic acid recep-
tor; RXRE, RXR-responsive element; RXR, retinoid X receptor; SNuRMS, specific
nuclear receptor modulators; SREBP, sterol regulatory element-binding protein; T3,
thyroid hormone; TRE, thyroid hormone-responsive element; TR, thyroid hormone
receptor; TSH, thyroid-stimulating hormone; VDR, vitamin D receptor.
Introduction
The retinoid X receptors (RXRs) comprise three isoforms
in humans (a, b, and c) (Leid et al. 1992; Mangelsdorf
et al. 1994) all of which act as sequence-specific DNA-
binding factors (transcription factors), often partnering
with other transcriptional regulators in a larger superfam-
ily of nuclear receptors including the liver X receptor
(LXR), the thyroid hormone receptor (TR), the retinoic
acid receptor (RAR), the vitamin D receptor (VDR), and
the peroxisome proliferator-activated receptor (PPAR), to
name a few. All of the above named nuclear receptors
promote or regulate gene transcription when associated
with the proper receptor ligand. This ligand, often con-
sisting of an endogenous molecule, associates with the
receptor ligand-binding domain (LBD) and this binding
effects a conformational change that induces the receptor
to interact with a corresponding hormone-responsive ele-
ment (HRE) in DNA. While many HREs are located
inside or proximal to the regulated gene’s promoter
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region, some HREs have been found considerably distant
either downstream or upstream from their controlled genes.
Typically, HREs comprise two minimal core hexad
sequences such as AGGTCA and variants, with the orienta-
tion and spacing between which determining the binding
mode (homodimer, heterodimer, or monomer) and iden-
tity of the nuclear receptor partner (Remenyi et al. 2004).
While VDR, TR, and RAR were first believed to bind
as homodimers to their corresponding HREs (Forman
et al. 1989), these nuclear receptors actually form hetero-
dimers with RXR in order to bind to their HRE sites
(Johnson et al. 1987; Mangelsdorf and Evans 1995).
When bound with an agonist ligand, such as naturally
occurring 9-cis-retinoic acid (9-cis-RA) or a synthetic ago-
nist such as bexarotene (1), RXR forms a homodimer that
subsequently associates with the RXR-responsive element
(RXRE). When RXR acts as a partner in a heterodimer
with another nuclear receptor, however, it may do so with
or without a ligand bound to RXR depending on the
heterodimer. For example, there is strong evidence that
the LBP (ligand-binding pocket) of RXR is vacant in the
functioning RXR-VDR heterodimer (Thompson et al.
2001). In the case of the RXR-LXR heterodimer, however,
the LBP of RXR can be occupied (Svensson et al. 2003).
Because of its ability to partner with numerous other
nuclear receptors and subsequently associate with the
heterodimer HRE, RXR has been described as the central
nuclear receptor (Nahoum et al. 2007). Indeed, the obser-
vation that RXR possesses multiple dimerization surfaces
to be able to pair with different nuclear receptors, yet it
still retains the flexibility to associate with each heterodi-
meric HRE, contributes to the view of RXR as the master
partner.
As observed earlier, there are two main classifications
into which RXR-heterodimer complexes can be divided.
These are commonly referred to as permissive or nonper-
missive heterodimers, respectively. Permissive heterodi-
mers can be actuated by either a ligand binding to RXR
or a ligand binding to its partner, whereas a purely non-
permissive heterodimer can only function when a ligand
binds to the primary (non-RXR) receptor (Forman et al.
1995). Nonpermissive heterodimers are generally exempli-
fied by RXR-VDR, RXR-TR, and RXR-RAR. For the most
part, but not always, RXR is “silent” in VDR and TR
heterodimers, whereas RXR-RAR heterodimers are further
activated by specific RXR ligands in addition to a RAR
ligand. In fact, in a few cases, RXR ligands have been
observed to promote RXR-RAR functioning, even when
an RAR ligand is absent (Lala et al. 1996). Hence, the
RXR-RAR heterodimer has been termed “conditionally”
nonpermissive. In comparison to the nonpermissive hete-
rodimers described earlier, the RXR-PPARs, RXR-FXRs,
and RXR-LXRs are completely permissive heterodimers.
Developing therapeutic RXR-selective ligands is chal-
lenging not only because permissive RXR heterodimers
may lead to off-target responses but also because in some
tissue types, the availability of RXR may be limited. For
example, the natural 9-cis-RA has been observed to inhi-
bit the activation of the nonpermissive RXR-VDR (Mac-
Donald et al. 1993; Lemon and Freedman 1996;
Thompson et al. 1998) and RXR-TR heterodimers (Leh-
mann et al. 1993). The development of novel RXR-selec-
tive ligands (rexinoids) for therapeutic uses must thus be
concerned with identifying compounds that exert RXR-
heterodimer selectivity. Indeed, the approach of designing
rexinoids that drive binding to specific nuclear receptor
modulators (SNuRMs) is a topic of current interest.
As an FDA-approved drug, bexarotene (1) is also often
used “off-label” to treat non-small cell lung cancer (Drag-
nev et al. 2007) and breast cancer (Esteva et al. 2003).
While 1 and related RXR agonists have primarily been
investigated as treatments for cancer, there have been
recent reports of the exploration of 1 as a potential thera-
peutic for neurological conditions and diseases. For exam-
ple, 1 was initially reported to clear amyloid plaques,
lower levels of amyloid beta (a-beta) oligomers, and
improve cognitive deficits in aggressive Alzheimer’s dis-
ease (AD) mouse models (Cramer et al. 2012). However,
some controversy surrounds the effectiveness of 1 in mur-
ine models of AD, since other groups replicating the ori-
ginal experiments did not observe similar reductions of a-
beta or cognitive improvements though some groups did
observe lowered levels of a-beta oligomers and cognitive
improvements (Fitz et al. 2013; Price et al. 2013; Tesseur
et al. 2013; Veeraraghavalu et al. 2013). One hypothesis
suggests that 1 exerts a therapeutic effect in AD by upre-
gulating ApoE (Holtzman 2004) and ABCA1 (Koldamova
et al. 2005) expression via the activation of RXR:LXR and
RXR:PPAR (Heneka et al. 2005), and this results in
higher concentrations of larger HDL particles that prevent
a-beta plaque formation (Fan et al. 2009). Indeed, on this
basis alone, two clinical trials for 1 in AD patients are
currently underway. Interestingly, a recent report by
Fantini et al. (2014) suggests that 1 may be effective in
preventing a-beta oligomers from forming calcium trans-
port channels in neuronal cells by disrupting the oligo-
mers’ ability to bind to cholesterol, while another report
(Tai et al. 2014) finds that 1 is more effective in later
stage AD using a humanized ApoE mouse model.
In addition to AD, schizophrenia and Parkinson’s dis-
ease (PD) are also neurological conditions for which 1
may exert a beneficial effect. In the case of schizophrenia,
there is strong evidence of retinoid dysregulation (Good-
man 1994) that could potentially be ameliorated by treat-
ment with a potent retinoid such as 1. Indeed, adding
treatment with 1 to antipsychotic medications has been
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shown to mitigate symptoms associated with schizophre-
nia (Lerner et al. 2008). In the case of PD, a recent report
by Burstein and coworkers suggests that 1 interacts with
the Nurr1-RXR heterodimer, at 100-fold lower doses than
used in treatment of cancer, to restore dopamine neurons
in rat models of PD (McFarland et al. 2013).
Although 1 is a potent RXR agonist, treatment for can-
cer at a dose up to 300 mg/m2 per day nonetheless raises
triglycerides–up to 2.5 times the upper limit of normal–as
well as total cholesterol for most patients, and more than
half of the patients experience hypothyroidism. While the
raised triglyceride and cholesterol levels were observed to
revert to normal levels following therapy cessation, the
triglyceride and cholesterol levels were also observed to be
clinically manageable with antilipidemic therapy during
treatment with 1 (Eisai 2001).
Given the numerous applications of 1 in the treatment
of several human cancers as well as its exploration as a
potential therapy for several neurological diseases, we
undertook the determination of pharmacokinetic parame-
ters and side effect profiles of several novel analogs of 1
and other potent RXR agonists that we have recently syn-
thesized. Our results show that the majority of our novel
analogs–in cell-based assays or in Sprague–Dawley rats at
100 and 30 mg/kg–possess activities and side effect pro-
files not statistically different than 1. However, in com-
parison with 1, several of our novel compounds are
potentially more bioavailable and thus could putatively be
more useful therapeutically since a lower dose could be
given than the standard dose (100 mg/kg) for 1. Thus,
our novel analogs represent theoretically viable therapeu-
tics for several human cancers and possibly for the neuro-
logical diseases noted earlier, and we are continuing to
explore their activities in these areas.
Materials and Methods
EC50 determination
Full doseresponse curves, ranging from 1 9 109 to
0.3 9 105 mol/L ligand in transfected HCT-116 cells
using an RXR mammalian two-hybrid system, were used
to generate EC50 values. HCT-116 (male Homo sapiens
colorectal carcinoma epithelium) cells were plated over-
night at 80,000 cells/well in a 24-well plate and main-
tained as described previously (Wagner et al. 2009;
Furmick et al. 2012; Jurutka et al. 2013). The cells were
cotransfected using a human RXR binding domain (BD)
vector, a human RXR activation domain (AD) vector, a
luciferase reporter gene containing BD-binding sites, and
Renilla control plasmid, using 2 lL/well of Express-IN
transfection reagent (Thermo Fisher Scientific, Lafayette,
CO) that was allowed to incubate for 24 h with the cells.
The cells were then treated with ethanol vehicle (0.1%) or
analogs (1.0, 2.5, 5.0, 7.5, 10, 25, 50, 75, 100, 250,
500 nmol/L, 1, 2, 3 lmol/L) and incubated for 24 h. The
amount of rexinoid activity at each concentration was
measured using the luciferase assay described earlier, and
EC50 values were calculated using doseresponse curves
of ligand concentration versus normalized luciferase activ-
ity.
TR activation assay
The reporter construct (TRE-Luc [thyroid hormone-
responsive element]) utilized for assaying TR signaling
was constructed by inserting the double-stranded oligonu-
cleotide, CTGGGAGGTGACAGGAGGACACGAGCTGG
GAGGTGACAGGAGGACACGAG, with a BglII overhang
on the 50 end and a HindIII overhang on the 30 end,
upstream of a minimal promoter in the luciferase vector
pLUC-MCS (Stratagene Corp., La Jolla, CA). This oligo-
nucleotide contains two copies of the thyroid HRE (half
sites are underlined) from the rat myosin heavy chain
gene (Tsika et al. 1990). HCT-116 colorectal carcinoma
cells were plated overnight at 80,000 cells/well in a 24-well
plate and maintained in Dulbecco’s modified Eagle’s
medium (DMEM)/High Glucose (Hyclone; GE Life Sci-
ences, Logan, UT) enhanced with 10% fetal bovine serum
(FBS) (Invitrogen, Life Technologies, Grand Island, NY),
1 mmol/L sodium pyruvate (Invitrogen, Life Technolo-
gies, Grand Island, NY), 100 lg/mL streptomycin (Invi-
trogen), and 100 U/mL penicillin (Invitrogen). The cells
were cotransfected using 250 ng of TRE-Luc reporter
gene, 50 ng of pSG5-hTR, and 20 ng of the Renilla con-
trol plasmid along with 2 lL/well of Express-IN transfec-
tion reagent (Thermo Fisher Scientific) used for
liposome-mediated DNA delivery for 18 h. The cells were
then incubated for 24 h post-transfection with ethanol
vehicle or bexarotene or analogs (final concentration of
1 9 107 or 5 9 107 mol/L). After a 24-h incubation
period, the amount of luciferase activity was measured
using a luminescence assay. The amount of TRE activity
was measured by luciferase output utilizing a dual-lucifer-
ase reporter assay system according to the manufacturer’s
protocol (Promega, Madison, WI) in a Sirius luminome-
ter (Berthold Detection System, Pforzheim, Germany).
Three independent assays were conducted with triplicate
samples for each treatment group. Significance was
analyzed by a two-tailed unpaired Student’s t-test.
TR-TRE inhibition assay
The TR-TRE inhibition assay was completed using HCT-
116 cells plated at 80,000 cells/well in a 24-well plate
and maintained as described earlier. The cells were
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cotransfected using 250 ng of the TRE-Luc reporter gene
(described earlier), 50 ng of pSG5-hTR, and 20 ng of the
Renilla control plasmid with 2 lL/well of Express-IN
again used for liposome-mediated DNA delivery for 18 h.
The cells were incubated for 24 h post-transfection with
ethanol vehicle, 106 mol/L thyroid hormone (T3)
alone, or 106 mol/L T3 in combination with bexaro-
tene or analogs (final concentration of 1 9 107 or
5 9 107 mol/L). After a 24-h incubation period, the
amount of luciferase activity was measured using the
luminescence assay described earlier. Three independent
assays were conducted with triplicate samples for each
treatment group. Inhibition of T3 activity was deter-
mined by evaluation of T3-treated cells compared to
cells treated with T3 plus bexarotene/analog. Signifi-
cance was analyzed by a two-tailed unpaired Student’s
t-test.
Sterol regulatory element-binding protein
activation assay
HCT-116 colorectal carcinoma cells were maintained as
described earlier. The cells were cotransfected using
250 ng of the pBP1c(6500)-Luc reporter gene which con-
tains an LXRE in the context of about 6500 base pairs of
flanking DNA from the mouse sterol regulatory element-
binding protein (SREBP)-1c natural promoter (Repa et al.
2000) along with 50 ng of CMX-hLXRa, 50 ng of pSG5-
hRXRa, and 20 ng of the Renilla control plasmid. The
transfection was initiated with 2 lL/well of Express-IN
transfection reagent (Thermo Fisher Scientific) used for
liposome-mediated DNA delivery for 18 h. The cells were
then incubated for 24 h post-transfection with ethanol
vehicle, 107 mol/L TO901317 alone, or 107 mol/L bex-
arotene/analogs alone, or the combination of the two
ligands. After a 24-h incubation period, the amount of
luciferase activity was measured using a luminescence
assay. The amount of SREBP promoter activity was mea-
sured by luciferase output utilizing a dual-luciferase
reporter assay system according to the manufacturer’s
protocol (Promega) in a Sirius luminometer (Berthold
Detection System). Three independent assays were con-
ducted with triplicate samples for each treatment group.
Significance was analyzed by a two-tailed unpaired
Student’s t-test.
Cyprotex toxicity and mutagenicity analysis
This analysis was performed in-house at Cyprotex Labs
(Watertown, MA). Each test compound is diluted into
dimethyl sulfoxide (DMSO), subsequently diluted into
water, and then added as a series of dilutions into a 96-
well plate. Methyl methanesulfonate is added as a positive
control for genotoxicity. The assay used two strains of
cultured human lymphoblastoid TK6 cells, the test strain
(GenM-T01) and the nonfluorescent control strain
(GenM-C01), the latter was used to allow correction for
any autofluorescence from the test compounds. The test
strain has incorporated a patented green fluorescent pro-
tein (GFP) reporter system that exploits the proper regu-
lation of the GADD45a gene, which mediates the adaptive
response to genotoxic stress; exposure to a genotoxic
compound increases expression of GFP.
Cells, media, and compound (1% DMSO final concen-
tration; either alone or activated by a rat liver S9 extract)
are added to a well to perform the assay. The microplates
are covered with a breathable membrane and incubated at
37°C with 5% CO2 and 95% humidity for 48 h. The
plates are analyzed at 24 and 48 h time points using a mi-
croplate reader, reading both cell density and GFP expres-
sion. Fluorescence is normalized to the absorbance signal
to correct for variation in cell yield caused by cytotoxicity.
Raw data collected from GreenScreen assay plates are
saved to an MS Excel file and analyzed by Cyprotex with
GreenScreen Software, Cyprotex Labs, Watertown, MA.
Animal dosing
All in vivo work was performed by Covance Laboratories
in Madison, WI. Covance has approval through the NIH
OLAW (Office of Laboratory Animal Welfare); their
assurance number is A3218-01. Approvals were obtained
both from Covance IACUC and ASU IACUC before
experiments commenced. All compounds were suspended
in sesame oil, as in the original analysis at Ligand Phar-
maceuticals (Howell et al. 2001) and as in other analyses
(Tai et al. 2014), due to the hydrophobic nature of the
compounds (Bolko et al. 2014) and to try to maximize
drug absorption (Eisai 2001), at a final concentration of
10 mg/mL. Male Sprague–Dawley rats (8–12 weeks old
and 250–350 g, obtained from Harlan Laboratories, India-
napolis, IN) were allowed to acclimate for over 2 days,
fasted 24 h prior to a single dose at a target concentration
100 mg/kg for lipid analysis and PK analysis (Howell
et al. 2001) and 30 mg/kg for thyroid-stimulating hor-
mone (TSH) analysis (Liu et al. 2002), and then allowed
to feed ad libitum 4 h post dose (Harlan Certified Rodent
Diet #2016C or 2016CM and clean water). Dosing was
done by oral administration using a blunt needle. Blood
was drawn from three animals at the indicated time
points, and processed for analysis. For lipid and pahrma-
cokinetic (PK) analysis, half of the sample was processed
for plasma and half was allowed to clot and processed for
serum. For TSH analysis, blood was drawn from animals
at the indicated time points and allowed to clot and pro-
cessed for serum.
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Lipid analysis
Serum was analyzed for cholesterol, high-density lipopro-
tein (LDL), low-density lipoprotein, and triglycerides
using a Lipid Profile Panel at Covance. For the LC-MS/
MS analysis, the plasma samples are prepared by liquid–
liquid extraction using ethyl acetate. Following extraction,
the supernatant is transferred to a new plate and evapo-
rated under nitrogen. The samples are then reconstituted
using mobile phase B for injection on the instrument.
The LC-MS/MS instrument comprised a Shimadzu HPLC
(Columbia, MD) and a API5000 mass spectrometer.
Chromatographic separation is achieved using a C18 col-
umn in conjunction with gradient conditions (ammo-
nium acetate/acetic acid in water [A] or 80:20 ACN:water
[B]). MS detection is accomplished through monitoring
of MRM transitions unique to each analyte in negative
mode. The calibration curves range from 1 to 20
(depending on the analyte) to 1000 ng/mL, and no QC
samples are included. The clinical pathology samples are
analyzed using a Roche Modular P instrument (InIdiana-
polis, IN).
TSH analysis
Serum was analyzed via enzyme-linked immunosorbent
assay (ELISA) (Catalog No. KT-29925; Kamiya Biomedi-
cal Company, Seattle, WA) for TSH concentration analy-
sis according to manufacturer’s instructions. An unpaired
heteroscedastic two-tailed Student’s t-test was employed
to determine if the decrease in the TSH in each case was
statistically different than the bexarotene treatment.
PK analysis
Plasma was analyzed via liquid chromatography and tan-
dem mass spectrometry for compound concentration.
Whenever possible, determination of maximum concen-
tration (Cmax), time to maximum concentration (Tmax),
and total area under the curve (AUC) was performed.
Pharmacokinetic parameters are calculated by noncom-
partmental analysis using WinNonlin Professional Edition
(Version 5.2; Pharsight Corporation, Princeton, NJ).
Nominal doses and sampling time points were used for
all groups.
UV-vis e and water solubility determinations
A 2.0 mmol/L stock solution in ethanol of 1, 2, 4, 7, 9,
and 14 was made from which e was determined from a
Beer’s law plot of dilutions. A 10 lmol/L solution in 10%
ethanol/water of 1 and each compound was also made by
dissolving 0.020 mmol of 1, 2, 4, 7, 9, and 14 in 200 mL
of ethanol and then diluting to 2.0 L with water. Dilu-
tions of the 10 lmol/L solution in 10% ethanol/water
were made to determine an equation for the Beer’s law
plot by linear regression. Saturated aqueous solutions at
20°C of 1, 2, 4, 7, 9, and 14 were prepared by placing
~25 mg of micronized compound in 10 mL of deionized
water and agitating, intermittently, for 24 h, and filtering
with a 0.22 lm Millipore filter (Darmstadt, Germany).
The water solubility of 1, 2, 4, 7, 9, and 14 was estimated
by solving the linear regression equation from the Beer’s
law plot for the 10% ethanol/water solutions with the
observed absorbance of the saturated aqueous solutions of
1, 2, 4, 7, 9, and 14.
pKa calculations
Absolute pKas were calculated using the thermodynamic
cycle shown in Figure 1 (Shields and Seybold 2013). All
protonated and deprotonated structures were geometry
optimized at the B3LYP/6-311+G(d,p) level, and the nat-
ure of the minimum was confirmed by harmonic fre-
quency calculations. The scaled frequencies (Merrick et al.
2007) were then used to calculate gas-phase free energies.
The solvation free energies DGs of the optimized struc-
tures were calculated using the SM8 continuum model
(Marenich et al. 2009) at the B3LYP/6-311+G(d,p) level.
For the proton, experimentally derived values of
6.28 kcal/mol for the gas-phase free energy and
264.61 kcal/mol for the solvation free energy were used.
All calculations were performed with Gaussian 09 (Frisch
et al. 2009).
RNA sequencing analysis
Brains from animals treated above were removed and
snap frozen in liquid nitrogen and then sent to LabCorp
Clinical Trials (formerly Covance Genomics Lab) where
they were suspended in 500 lL of RLT buffer (Qiagen,
Valencia, CA) containing b-mercaptoethanol and homog-
enized using a Covaris homogenizer (Woburn, MA). Fol-
lowing trizol/chloroform treatment, RNA was extracted
gas
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sagsagsag
s s s
qaqaqa
(AH) (A ) (H )
G
G
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G G G
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Figure 1. Thermodynamic cycle used in calculating pKa.
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using Promega SV96 isolation kits. RNA was qualified
using an Agilent Bioanalyzer and quantified using ribo-
green. RNA_Seq libraries were constructed using Illu-
mina’s TruSeqTM Total RNA strand specific kits (San
Diego, CA) with 250 ng of total RNA. Briefly, rRNA was
removed from FF or FFPE total RNA using Epicentre’s
Ribo-Zero GOLD rRNA Removal kit (Madison, WI).
Ribo-Zero RNA was then incubated with Random Prim-
ers (Invitrogen, Grand Island, NY) at 65°C for 5 min.
Illumina TruSeqTM RNA Sample Prep Kit was then used
to construct the library according to the manufacturer’s
protocol from the step of first strand cDNA synthesis.
The sequencing libraries were quality controlled using an
Agilent 2100 Bioanalyzer and quantified using qPCR prior
to cluster generation on an Illumina cBot. Sequence data
were generated on Illumina HiSeq instruments as paired
end 51-bp reads, following the manufacturer’s protocols
using TruSeq SBS v3 chemistry. An in-house pipeline for
analysis, which integrates several open source programs,
was used to analyze data. Briefly, initial FASTQ files were
subjected to quality control with the FastQC tool. Raw
reads from each capture library were aligned to the rat
reference genome (rn5) with STAR version 2.3.1r, using
default parameters. Expressed transcriptome was built
using Cufflinks (version 2.1.1) and was annotated using
cuffmerge (Cufflinks version 2.1.1). The rn5 refGene.gtf
annotation (UCSC), filtered to include only canonical
chromosomes was used as the reference GTF.
Results
Rexinoid structures and EC50 values
Figure 2 depicts the structures of the compounds we uti-
lized for the assays. Bexarotene (1) is the standard by
which the rexinoids were compared, as it is the FDA-
approved drug. Characteristics of these compounds and
their synthesis were described in our previous work
(Wagner et al. 2009; Furmick et al. 2012; Jurutka et al.
2013). In Table 1, we summarize the EC50 values for these
compounds.
TRE activation via select rexinoids
In order to assess potential side effect differences between
our rexinoids, we first utilized a cell culture model. We
assessed the ability of each rexinoid to bind to RXR and
allow the receptor to act as a permissive partner to acti-
CO2H
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N
O
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N
O
OH
N
N
O
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N
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O
OH
F
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Figure 2. Structures of rexinoids analyzed in this article.
2015 | Vol. 3 | Iss. 2 | e00122
Page 6
ª 2015 Arizona State University. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Rexinoids With Differential Side Effect Profiles P. A. Marshall et al.
vate an RXR/TR heterodimer in the absence of thyroid
hormone (Castillo et al. 2004) at two concentrations
(1 9 107 and 5 9 107 mol/L). The cells were transfect-
ed with TR and a TRE (thyroid hormone-responsive ele-
ment) driving a luciferase reporter gene, so that RXR was
in limiting concentrations. As can be seen in Figure 3,
each rexinoid (except analog 8) can significantly
(P < 0.05) stimulate RXR to act as a permissive partner
(in the absence of thyroid hormone) with the TR at
1 9 107 mol/L of analog (Fig. 3A), but not at
5 9 107 mol/L (Fig. 3B). Since RXR is limiting, at a
higher concentration of ligand (5 9 107 mol/L) the
rexinoids may be driving formation of RXR homodimers
rather than acting to stimulate RXR/TR heterodimers,
and/or some of the analogs result in a TR-RXR heterodi-
mer conformation that recruits corepressors to the tran-
scriptional complex resulting in either no activation or
even repression below ethanol vehicle levels (Fig. 3B, ana-
logs 8, 11–14).
Rexinoid inhibition of T3-stimulated TR-TRE
transcription
Hypothyroidism is a widely reported problem with bex-
arotene treatment (Sherman et al. 1999), and is thought
to occur partly because bexarotene stimulates RXR ho-
modimers, which in turn diverts the RXR away from
partnering with TR. We utilized a TRE-linked reporter
vector and cell culture system in which cells were treated
with both a thyroid hormone (T3) and a rexinoid to
determine the percentage of inhibition by the rexinoid
treatment. In this system, RXR is limiting and thus add-
ing a rexinoid should stimulate RXR homodimerization,
and remove the RXR from the RXR/TR heterodimer,
blunting the T3 response, as assayed by TRE activation.
As shown in Figure 4, each rexinoid demonstrates a dif-
ferent inhibition profile, with analogs 3 and 8 demon-
strating the most inhibition at 1 9 107 mol/L (Fig. 4A,
P < 0.01) and at 5 9 107 mol/L (Fig. 4B) analogs 3, 4,
6, 7, 8, 12, 13, and 14 inhibit the TRE-mediated activa-
tion significantly (P < 0.01).
More important than the inhibition profile, is the series
of analogs that show little inhibition in this assay. This
lack of inhibition hints that rexinoids, even with excellent
RXRE activation profiles (Wagner et al. 2009; Furmick
et al. 2012; Jurutka et al. 2013), and EC50s comparable to
bexarotene (Table 1) can be synthesized that, with the
correct chemistry and binding profile, may alleviate or
minimize thyroid hormone axis side effects. At a concen-
tration of 1 9 107 mol/L, compounds 2, 5, 6, 7, 10, 11,
12, 13, and 14 demonstrate at least 85% (or more) of the
activity of T3 alone (second bar from left), with less inhi-
bition than 1 (bexarotene), and indeed 2, 5, 6, 7, 10, 12,
and 13 are statistically the same as T3 alone (using a two-
tailed heteroscedastic t-test). While at treatment concen-
tration of 5 9 107 mol/L, we observe that compounds 9
and 10 show no inhibition of the T3 stimulation. Our
novel results indicate that it is possible to uncouple the
thyroid inhibition from the RXRE activation of rexinoid
compounds and suggests a potential method to alleviate
one of the untoward side effects of rexinoid treatment.
Activation of SREBP promoter-induced
transcription of rexinoids
In order to assess potential lipid profile side effects, analy-
sis of transcription driven by the SREBP promoter was
undertaken. SREBP is a transcription factor that drives
expression of genes involved in lipid synthesis by binding
to a sterol regulatory element in DNA and promoting
transcription. SREBP expression is driven in part by
RXR/LXR binding to the SREBP promoter and stimulat-
ing transcription. To determine the ability of each rexi-
noid to stimulate SREBP expression, as a proxy for
analysis of lipid anomalies induced by rexinoid treatment,
we analyzed luciferase expression driven by the SREBP
promoter in cells treated with rexinoid alone or in combi-
nation with T0901317 (T0), an LXR selective ligand. Each
rexinoid was analyzed for its ability to stimulate tran-
scription (Fig. 5) with and without T0, and we observed
a range of activities. With analog alone, compounds 2, 3,
4, 9, 10, and 13 demonstrated a similar transcriptional
profile to bexarotene; while the remainder of the com-
pounds showed an increased transcriptional response
(P < 0.05, using a two-tailed heteroscedastic t-test). In
Table 1. EC50 values of compounds evaluated in this study.
Compound EC50 value
1 nmol/L (SD)
Compound 1 55 (6)
Analog 2 34 (6)
Analog 3 13 (3)
Analog 4 42 (3)
Analog 5 74 (7)
Analog 6 21 (2)
Analog 7 44 (12)
Analog 8 15 (3)
Analog 9 50 (10)
Analog 10 72 (11)
Analog 11 15 (2)
Analog 12 69 (7)
Analog 13 109 (8)
Analog 14 71 (10)
RXR, rexinoid X receptor.
1EC50 values were determined from full dose–response experiments
with each compound in the range of 109 to 105 mol/L in transfect-
ed HCT-116 cells using an RXR mammalian two-hybrid system.
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analyzing rexinoids with T0, we saw a similar pattern,
with compounds 2, 4, 7, 10, 12, and 13 possessing similar
activation to bexarotene (1) + T0 treatment. In contrast,
with analog plus T0 treatment, only compounds 3 and 9
demonstrated lower SREBP promoter activation
(P < 0.05). Interestingly, compounds 5, 6, 8, 11, and 14
showed higher activation (P < 0.05, using a two-tailed
heteroscedastic t-test).
Select rexinoids show similar cytotoxicity
profiles to bexarotene
Considering multiple characteristics, such as transcrip-
tional activation of RXR based on reported EC50 values
(Table 1) and performance in SREBP promoter activation
assays (Fig. 5), we selected compounds 2, 4, 7, 9, and 14
as compounds to further explore as potential leads. To
assess cytotoxicity and mutagenicity of these compounds
prior to any in vivo studies, a GreenScreenTM assay was
performed by Cyprotex. Compounds are solubilized in
DMSO and added at several concentrations to a geneti-
cally modified human lymphoblastoid TK6 cell line, car-
rying the GFP gene driven by the GADD45a promoter.
Compounds were either added alone or after activation
with an S9 rat liver extract. Cytotoxicity was measured by
a cell viability assay and genotoxicity (mutagenicity) was
assayed by GFP fluorescence normalized to cell count. As
seen in Table 2, bexarotene (1) is cytotoxic at 1.12 lg/mL
without S9 activation and at 18 lg/mL with S9 activation,
and is not genotoxic. These novel rexinoids show similar
ranges of cytotoxicity as bexarotene, and only 14 demon-
strates genotoxicity, at the same concentration that it is
demonstrated to be cytotoxic; thus, this genotoxicity
would never be clinically relevant as the dose is too high
to be useful because that dose is also cytotoxic as well.
Notably, 9, an analog of LGD100268, was the least
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Figure 3. Thyroid hormone-responsive element (TRE) activation of select analogs. HCT-116 cells were transfected with thyroid receptor and a TRE
driving luciferase, and luciferase activity was plotted as percentage of T3 response, which was normalized to 100%. Cells were treated with
1 9 106 mol/L T3 and 1–4 at (A) 1 9 107 mol/L and (B) 5 9 107 mol/L for 24 h.
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cytotoxic without S9 activation (up to 8.57 lg/mL), and
9 was the only analog that showed no cytotoxicity or
genotoxicity with S9 activation. Thus, these new rexinoids
have potential as therapeutics as they demonstrate similar
toxicity patterns to bexarotene.
Select rexinoids have the same primary TSH
phenotype as bexarotene
Bexarotene treatment often induces hypothyroidism in
patients (e.g., Sanchez-Juan et al. 2007). In order to assess
the side effect profiles of our novel rexinoids, male
Sprague–Dawley rats were dosed at 30 mg/kg and TSH
was assayed over a 24 h time course. The suppression of
TSH occurs acutely due to the inhibition of the secretion
of TSH from the pituitary (Liu et al. 2002), but after
16 h (or less) this inhibition is due to repression of the
TSH promoter itself (Sherman et al. 1999). As seen in
Figure 6, TSH decreased in all animals treated with rexi-
noid in the same manner with the same time course as
bexarotene (1), with no statistically significant differences,
indicating that these RXR ligands have no worse side
effect profile over the first 24 h of treatment than the
parent compound, bexarotene.
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Figure 4. Select rexinoids inhibit thyroid hormone-responsive element (TRE) activation by T3. HCT-116 cells were transfected with thyroid
receptor and a TRE driving luciferase, and luciferase activity was plotted as percentage of T3 response, which was normalized to 100%. Cells
were treated with 1 9 106 mol/L T3 or with 1–14 at (A) 1 9 107 and 106 mol/L T3 and (B) 5 9 107 and 106 mol/L T3, for 24 h.
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Select rexinoids show distinct lipid profiles
from bexarotene (1)
Bexarotene (1) treatment increases plasma triglycerides
and cholesterol in patients (e.g., Sanchez-Juan et al.
2007). To evaluate our rexinoids for potential differences
in side effects, we treated male Sprague–Dawley rats with
a single dose of 100 mg/kg bexarotene or analog and
assessed cholesterol, LDL, HDL, and triglycerides at
several time points.
Treatment of rats with 1 mimics published studies in
mice, and several analogs have similar side effect profiles.
In rats treated with 1, total cholesterol actually goes down
over a 24 h period (Table 3). This is reminiscent of mice
treated with 1, where the drop in total cholesterol is pos-
tulated to be due to inhibition of absorption of dietary
cholesterol (de Vries-van der Weij et al. 2009). Only ana-
log 14 has statistically significantly different (higher) cho-
lesterol than bexarotene at 9 and 24 h. Treating rats with
rexinoids generally did not affect the HDL (Table 4), and
decreases the LDL (Table 5), similar to studies performed
in mice (de Vries-van der Weij et al. 2009).
Only the triglyceride profiles of rats treated with 1 or
any of the analogs differed significantly over the time
course (Table 6). Triglycerides increase in patients treated
with 1 (Sanchez-Juan et al. 2007) and this clinically is the
most troublesome side effect in the lipid metabolism
pathway, due to the predisposition to atherosclerosis and
cardiovascular disease (Talayero and Sacks 2011). After
24 h, analog 14 induced significantly higher triglycerides
(1589  820.9 ng/dL vs. 279  67.1 ng/dL with 1 treated
animals), and rats treated with analogs 4 (109  16.4 ng/
dL) and 9 (158  46.5 ng/dL) had lower triglycerides
than rats treated with bexarotene. Thus, we have devel-
oped a series of rexinoids that can modulate lipid chemis-
try differently, although these analogs all bind and
activate RXR in a similar manner (Wagner et al. 2009;
Furmick et al. 2012; Jurutka et al. 2013).
Pharmacokinetic profiles of bexarotene and
select rexinoids in rats
We were interested in determining the pharmacokinetic
profiles of bexarotene and several analogs in order to
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Figure 5. Select rexinoids potentiate SREBP promoter activation in the presence of T0901317. HCT-116 cells were transfected with LXRa, RXRa,
and the SREBP promoter driving luciferase, and luciferase activity was plotted as percentage of T0901317 response (crosshatched bar), which was
normalized to 100%. Cells were treated with 1 9 107 mol/L analog with or without 1 9 107 mol/L T0901317 for 24 h. LXR, liver X receptor;
RXR, rexinoid X receptor; SREBP, sterol regulatory element-binding protein.
Table 2. GreenScreenTM (Cyprotex) analysis of rexinoids for cytotoxicity
and mutagenicity.
Without S9 activation With S9 activation
Cytotoxicity
(lg/mL) Genotoxicity
Cytotoxicity
(lg/mL) Genotoxicity
1 1.12 None 18 None
2 0.74 None 47.3 None
4 1.33 None 21.3 None
7 6.64 None 213 None
9 8.57 None None None
14 1.06 None 33.9 33.9 lg/mL
Rexinoids were added to TK6 cells to assess cytotoxicity and mutage-
nicity, as assayed by cell viability (cytotoxicity) and GFP expression
(mutagenicity). Shown is the lowest effective concentration (LEC) for
a positive result.
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Figure 6. TSH levels in rats treated with rexinoids. TSH decreases in rats treated with bexarotene (1) or analogs. Male rats were treated with
30 mg/kg compound and blood was drawn predose, at 6, 12, and 24 h. TSH was quantitated by ELISA and represented as percentage of
predose levels. TSH, thyroid-stimulating hormone.
Table 3. Blood cholesterol concentration after treatment of 100 mg/kg compound or vehicle control.
Predose 1 h 2 h 3 h 6 h 9 h 12 h 24 h
Vehicle 110  12.5 104  12.1 94  11.2 93  8.4 101  9 103  13.4* 94  8.7* 82  2.1*
Bexarotene 105  7.2 108  14.4 93  15.3 91  9.6 89  15.6 73  10.7^ 61  13.8^ 52  6.6^
2 100  21.2 122  17.2 78  6.2 95  16.5 71  12.8^ 80  14 65  13^ 47  8^
4 106  1 100  16.1 87  4.9 81  14.8 83  7.5^ 66  15.1^ 66  10.6^ 50  11^
7 108  12 107  20.1 92  17.5 85  12.9 89  16 73  10.7^ 62  4.7^ 47  7.5^
9 91  8.1 99  7.5 81  6.5 80  10.8 75  4.7^ 68  9.9^ 50  4.5^ 49  5.7^
14 111  13.7 124  6.7 98  9.0 102  12.5 97  10.4 93  12.5* 72  11.9^ 100  21*
Male Sprague–Dawley rats were treated with 100 mg/kg compound in sesame oil or sesame oil alone (vehicle control). Blood was taken at the
indicated time points and analyzed for cholesterol composition in mg/dL. Statistical analysis was performed using a one-tailed Mann–Whitney test.
Statistically significantly different than: *bexarotene treatment P ≤ 0.05; ^vehicle control P ≤ 0.05.
Table 4. Plasma high-density lipoprotein concentration after treatment of 100 mg/kg compound or vehicle control.
Predose 1 h 2 h 3 h 6 h 9 h 12 h 24 h
Vehicle 86  14 85  12.6 73  11.9 67  10.8 55  4.0 65  7.5 55  6.4* 68  4.5*
Bexarotene 83  2.9 82  15.2 63  8.0 57  9.0 47  7.0 55  7.0 34  3.2^ 37  7.6^
2 82  16.4 109  11.8*^ 67  3.5 84  13.6* 52  10.8 61  3.8 46  12.1 30  4.4^
4 81  2.0 79  13.2 66  6.1^ 57  10.0 50  4.0 56  11.6 39  5.0^ 43  9.5^
7 81  10.8 74  4.0 65  13.1 54  6.4 52  12.3 48  20.0 30  10.8^ 37  3.1^
9 71  6.9* 81  3.6 65  7.0 59  4.2 47  6.0 51  3.2^ 33  4.9^ 41  3.6^
14 89  7.2 99  7.0*^ 80  7.5* 76  12.8 58  11.0 59  7.0 39  3.2^ 61  23.4
Male Sprague–Dawley rats were treated with 100 mg/kg compound in sesame oil or sesame oil alone (vehicle control). Blood was taken at the
indicated time points and analyzed for HDL composition in mg/dL. Statistical analysis was performed using a one-tailed Mann–Whitney test.
*indicates statistically significantly different than bexarotene treatment P ≤ 0.05; ^indicates statistically significantly different than vehicle control
P ≤ 0.05.
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determine if any rexinoid would show promise for addi-
tional research. As can be seen in Table 7 and Figure 7,
the PK profiles of the RXR ligands varied markedly.
Although each rat received the same 100 mg/kg dose,
Cmax (peak plasma concentration) varied greatly, from a
low of 4913 ng/mL in analog 4 to a high of 44,000 ng/
mL for analog 7. All of the analogs have short Tmax, of
between 1 and 2 h. Although, interestingly, AUC
does not always correlate with Cmax, as some of the
compounds may have a very long half-life (Fig. 7). For
example, although the peak plasma concentration of bex-
arotene (1) is 8,523 ng/mL, the AUC is 51,531 ng/mL,
more similar to 9. Compound 14 appears to be cleared
least effectively (Fig. 7) and 4 is at the lowest concentra-
tion in the plasma after 24 h.
Solubility and calculated pKa of rexinoids
studied in rats
The compounds demonstrated such different Cmax and
AUC values, as well as PK profiles (Fig. 7), we hypothe-
sized that these properties of the compounds were
affected by the physiochemical properties of the com-
pounds. To explore this possibility, we performed water
solubility determinations and calculated the pKa values
for 1 and analogs 2, 4, 7, 9, and 14.
Water solubilities, as well as UV-vis absorptivity con-
stants in pure ethanol and 10% ethanol/water (v/v), for 1
and analogs 2, 4, 7, 9, and 14 were determined at 20°C
and summarized in Table 8.
As might be expected, the difluoro-bexarotene analog
(2) was more soluble (58 lmol/L) than 1 (0.28 lmol/L),
Table 5. Plasma low-density lipoprotein concentration after treatment of 100 mg/kg compound or vehicle control.
Predose 1 h 2 h 3 h 6 h 9 h 12 h 24 h
Vehicle 31  6.1 25  5.0 22  4.0 22  3.1 29  3.8* 30  9.5* 25  6.4* 20  1.5*
Bexarotene 30  4.0 27  8.0 19  5.0 16  3.8 6  2.6^ 7  1.2^ 5  4.0^ 3  0^
2 26  7.6 27  6.1 14  6.1^ 13  3.6^ 7  1.5^ 6  1.2^ 7  2.0^ 3  0^
4 28  2.1 27  8.0 15  8.0^ 14  7.5 7  3.5^ 8  3.0^ 5  1.5^ 7  0*^
7 33  1.7 36  11.1 19  11.1 19  8.1 13  1.5*^ 11  7.0^ 6  2.5^ 4  1.0^
9 25  4.2 27  3.5 16  3.5 15  4.5 9  5.5^ 7  2.1^ 5  1.5^ 4  1.2^
14 33  5.3 35  2.6^ 19  2.6 18  2.5 9  3.6^ 5  2.5^ 4  1.0^ 3  0^
Male Sprague–Dawley rats were treated with 100 mg/kg compound in sesame oil or sesame oil alone (vehicle control). Blood was taken at the
indicated time points and analyzed for LDL composition in mg/dL. Statistical analysis was performed using a one-tailed Mann–Whitney test.
*indicates statistically significantly different than bexarotene treatment P ≤ 0.05; ^indicates statistically significantly different than vehicle control
P ≤ 0.05.
Table 6. Blood triglyceride concentration after treatment of 100 mg/kg compound or vehicle control.
Predose 1 h 2 h 3 h 6 h 9 h 12 h 24 h
Vehicle 41  8.4 75  11.8 84  11 114  33.3 144  86.7* 123  49.8 115  47.1 48  12.1*
Bexarotene 35  13.1 85  21.4 98  18.5 157  79 444  220.7^ 160  65.4 233  138.9 279  67.1^
2 35  8.0 50  19.1 53  14.5*^ 123  38.9 191  56.7 221  99.6 181  12.2^ 436  226.8^
4 50  8.1 68  5.9 118  21.6^ 146  36.9 357  306.9 123  27 269  101.5^ 109  16.4*^
7 38  7.2 71  29.6 130  50.8 164  122.3 217  60.1* 290  313.3 352  355.3* 193  77.3^
9 40  15.6 36  6.4*^ 82  16.5 118  8.9 229  93.0 177  121.0 136  22.2* 158  46.5*^
14 37  6.4 33  1.7 *^ 98  18.2 113  7.8 268  58 340  181.7^ 286  73.7^ 1589  820.9*^
Male Sprague–Dawley rats were treated with 100 mg/kg compound in sesame oil or sesame oil alone (vehicle control). Blood was taken at the
indicated time points and analyzed for triglyceride composition in mg/dL. Statistical analysis was performed using a one-tailed Mann–Whitney test.
*indicates statistically significantly different than bexarotene treatment P ≤ 0.05; ^indicates statistically significantly different than vehicle control
P ≤ 0.05.
Table 7. Pharmacokinetic profiles of 1 and analogs 2, 4, 7, 9, and 14
in male Sprague–Dawley rats that were treated with 100 mg/kg
compound in sesame oil.
Compound
Cmax
(ng/mL) Tmax (h)
AUC0–t
(h 9 ng/mL)
AUC0–inf
(h 9 ng/mL)
Bexarotene 8,523.33 2 51,531.67 54,329.87
2 2,406.67 1 20,539.37 ND
4 4,913.33 2 24,650.67 24,735.07
7 44,000.00 1 83,343.87 83,984.92
9 25,400.00 1 50,444.23 51,483.03
14 18,633.33 1 152,955.83 ND
Rats were treated with compound and blood samples were taken to
determine pharmacokinetic profiles by liquid chromatography and
tandem mass spectrometry. ND, not determined; AUC, area under
the curve.
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whereas the acrylic acid analog (4) possessed a water sol-
ubility (7.6 lmol/L) more similar to 1. The two analogs
possessing a pyrimidine ring, 7 and 9, also possessed
fairly high solubilities at 49 and 67 lmol/L, respectively.
The mono-fluoro-unsaturated bexarotene analog (14) had
an observed solubility of 15 lmol/L. While the analog
solubilities were not proportional to Cmax in all cases, and
an analog’s absorption and distribution may depend on
several factors such as pKa and lipophilicity, it is interest-
ing to note that the analogs with two of the three highest
measured water solubilities (7 and 9) possessed the two
highest measured values for Cmax.
We were also interested in assessing whether the pKa
of the analog could impact its absorption. Hence, we cal-
culated each of the tested compound’s pKa values
(Table 8 and Fig. 8). All analogs are weak acids, with the
exception of 2 whose pKa was fairly low at 0.4. It is
generally known that the unionized form of compounds
is more easily absorbed in the stomach. When disregard-
ing 2, the calculated pKa values showed strong anticorre-
lation between Cmax, AUC0–t, and AUC0–inf, with
regression coefficients of 0.68, 0.79, and 0.72,
respectively (Fig. 8). In addition, the compound possess-
ing the lowest pKa (2) also possessed the lowest
measured Cmax.
Expression comparison of compounds and
vehicle demonstrate differential expression
of genes after treatment of RXR ligands
Because the in vitro data hinted the analogs might have
differential effects, and due to the fact that the PK profiles
Table 8. Solubilities and calculated pKa for compounds analyzed in rats.
Compound kmax EtOH (nm) eEtOH ([mol/L]
1cm1)
kmax 10%
EtOH/Water (nm)
e10% EtOH/Water
([mol/L]1cm1)
Water solubility
at 20°C (lmol/L) pKa
[1] Calc’d
1 260 17,000 260 14,000 0.28  0.02 3.5
2 246 17,000 243 15,000 58  1 0.4
4 284 24,000 283 18,000 7.6  0.1 3.9
7 252 20,000 243 19,000 49  1 1.8
9 221 (sh) 19,000 220 25,000 67  1 1.7
14 252 17,000 244 17,000 15  1 1.1
A 2.0 mmol/L stock solution in ethanol of each compound was made from which e was determined from a Beer’s law plot of dilutions. A
10 lmol/L solution in 10% ethanol/water of each compound was also made by dissolving 0.020 mmol of each compound in 200 mL of ethanol
and then diluting to 2 L with water. Dilutions of the 10 lmol/L solution in 10% ethanol/water were made to determine an equation for the
Beer’s law plot by linear regression. The water solubility of each compound was estimated by solving the linear regression equation from the
Beer’s law plot for the 10% ethanol/water solutions with the observed absorbance of saturated aqueous solutions of each compound. Water solu-
bility estimates from measured absorbances are shown as the mean  standard deviation or the last significant digit, whichever is greater.
1Calculated pKa values, performed in Gaussian 9.0, using the thermodynamic cycle in Figure 1.
1 
10 
100 
1000 
10,000 
100,000 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
P
la
sm
a 
co
nc
en
tr
at
io
n 
in
 n
g/
m
L
Time in hours
Pharmacokinetic profile of select rexinoids
1 2 4 7 9 14 
Figure 7. Plasma concentration of rexinoids over a 24 h time course after a single dose of 100 mg/kg.
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and the chemical properties of the RXR ligands were so
different, we further hypothesized that each analog could
be inducing diverse cellular effects. In order to demon-
strate that each analog was novel in its cellular and
molecular effects, we analyzed the expression profiles
induced in the rats after analog administration. The
brains of the rats were snap frozen 24 h after the treat-
ment and then RNA was extracted and subjected to
sequencing analysis to compare expression between treat-
ments. Our analysis demonstrated that each analog
induced and repressed a different suite of genes (Fig. 9
and Table 9). For example, in Figure 9, rats treated with
7 demonstrated the most upregulation of genes (yellow
and orange) compared to bexarotene-treated rats; and rats
treated with 9 demonstrated the most disparate gene
expression to rats treated with bexarotene. In Table 9, we
see specific genes that are differentially regulated when
rats are dosed with RXR ligands. For example, the gene
Stra6 is upregulated in the brains of rats treated with 9
and highly upregulated when treated with 2, but slightly
repressed in the brains of rats treated with bexarotene or
7. Mir346, a small RNA implicated in inflammation, is
downregulated in bexarotene-treated rats but upregulated
in rats treated with 4, 7, and 9. Table 9 outlines differen-
tial regulation of a wide variety of genes, demonstrating
that these RXR ligands, although somewhat similar in
structure, are varied in their induction of molecular
events. Thus, these RXR ligands demonstrate differential
effects at the molecular and cellular levels, as demon-
strated by their expression profiles.
Discussion
We wished to explore not only the effects in vivo of ana-
logs bearing a close resemblance to bexarotene–as with 2,
7, and 14–but also analogs of other reported potent RXR
agonists. While all three analogs of bexarotene, 2, 7, and
14, possess electron withdrawing groups on the ring bear-
ing the carboxylic acid, 7 relies on two nitrogen atoms of
a pyrimidine ring, whereas both 2 and 14 possess fluorine
atom(s) proximal to the carboxylic acid group. We exam-
ined not only the effects in vivo of the potent difluorinat-
ed 2 but we were also interested to see how effects might
differ in comparison to 14 that places a single fluorine
proximal to the carboxylic acid group of 1 and possesses
one additional degree of unsaturation in the aliphatic
ring of 1. As for the other two chemical motifs from
which we selected analogs to test in vivo, LGD100268 (8)
differs from bexarotene by substituting a pyridine ring
for the phenyl ring of bexarotene that bears the carbox-
ylic acid group, and 8 also possesses a cyclopropyl ring
bridging the two aromatic rings. In addition to a report
showing 8 to be more potent than bexarotene in COS-1
cells by one order of magnitude (Boehm et al. 1995),
there are numerous reports of 8 serving as an effective
RXR agonist both in vitro (Boehm et al. 1995; Mu et al.
2000) and in vivo (Liu et al. 2002). In compound 9, we
devised an analog of 8 that possesses one additional
nitrogen atom by substituting a pyrimidine ring for the
pyridine ring of 8. We were encouraged that cytotoxicity
experiments (GreenScreen, Cyprotex, Watertown, MA)
identified 9 to be the least toxic of all compounds evalu-
ated prior to in vivo work, and we were eager to evaluate
this compound’s in vivo effects in comparison to 1.
Finally, we wished to assess a potent RXR agonist analog
of CD3254 (3) that substituted a methyl group (4) for
the hydroxyl group of 3 to determine if this type of
biphenyl framework for a potent RXR agonist had similar
or markedly different effects than 1.
The analysis of the SREBP promoter transactivation
data in cultured human cells, as compared with the rat in
vivo lipid data, yields remarkable similarities. The most
striking differences in the lipid profile in the rat model
were seen in the triglyceride concentrations. For the rats
treated with compound 4, between 1 and 12 h results
were similar to those treated with bexarotene. This is
comparable to Figure 5, in which we can see that cells
treated with compound 4 (with or without T0) show sim-
ilar activation of the SREBP promoter when compared to
Figure 8. Plots of Cmax, AUC0–t, and AUC0–inf versus calculated pKa
for 1, 2, 4, 7, 9, and 14. AUC, area under the curve.
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bexarotene. For the rats treated with compound 7, lipid
profiles are statistically identical to the rats treated with
bexarotene, and the same relationship is seen in the cells
treated either with or without T0. Finally, and most strik-
ingly, cells treated with compound 14, either with or
without T0 had the highest transcriptional response in
human cell culture; in rats, the triglyceride concentrations
at 24 h were incredibly high (1589  820.9 mg/dL), simi-
lar to the cells treated with this compound.
There are differences between the TRE activation pro-
files of the analogs at the two different concentrations
(Fig. 3A and B). In general, the cells treated with
1 9 107 mol/L rexinoid seem to generate slightly more
active TRE-based transcription. We speculate that at the
high dose of 5 9 107 mol/L the rexinoids may be
depleting the limiting pool of TR coactivators, perhaps
including SRC1, SRC2, SRC3 (Stashi et al. 2014),
TRAP100, and TRAP220 (Ito and Roeder 2001). Since
there is endogenous RXR in the cells, some of those RXRs
become active RXR-RXR homodimers, which then inter-
act with these coactivators and more RXR-RXR homodi-
mers complexed with coactivators will be formed at the
higher dose. That pool of RXR-RXR homodimers will not
bind the TRE, but still could influence TRE activity
because they titrate away the limiting pool of coactivators
that are in the cell, and those same coactivators are
needed for the TRE-driven transcription (by the RXR-TR
still bound to the TRE). This is because our assay system
Table 9. Differential expression of genes in rat brain after 24 h treatment with RXR ligand.
Gene Protein 1 2 4 7 9 14
Inmt Indolethylamine N-methyltransferase 0.23 1.93 0.41 0.82 0.36 0.13
Ccl6 Chemokine (C-C motif) ligand 6 0.054 0.66 0.91 1.46 1.39 1.68
Mta2 Metastasis-associated 1 family, member 2 0.97 1.88 0.10 1.36 0.34 1.45
Cyp26b1 Cytochrome P450 family 26, subfamily B, polypeptide 1 0.020 1.94 0.15 0.28 0.07 0.090
Stra6 Retinol-binding protein receptor 0.05 1.58 0.23 0.05 0.13 0.22
Angpt14 Angiopoietin-related protein 4 0.18 0.28 0.31 1.11 0.64 1.43
Pdk4 mt pyruvate dehydrogenase lipoamide kinase isozyme 4 0.77 0.87 0.04 0.44 0.07 0.61
Nmb Neuromedin B 0.166 1.28 0.33 0.38 0.20 1.00
Epha3 EPH receptor A3 0.34 0.89 0.27 0.34 0.007 0.49
Lyve1 Lymphatic vessel endothelial hyaluronan receptor 1 0.093 0.79 0.13 0.049 0.097 0.052
LOC689600 Uncharacterized and highly conserved 0.52 0.99 0.43 0.53 0.037 0.55
Vom2r8 Vomeronasal 2 receptor, 8 0.21 0.27 0.62 0.074 0.85 0.51
Mir346 microRNA 346 0.12 0.002 0.81 0.17 0.52 0.30
Acot1 Acyl-CoA thioesterase 1 0.31 0.02 0.41 0.93 0.65 1.14
Mir3556b microRNA mir-3556b 1.13 0.95 0.23 0.38 0.14 0.11
Cyp26a1 Cytochrome P450 26A1 0.46 1.00 0.061 0.088 0.002 0.15
Abca1 ATP-binding cassette transporter ABCA1 0.025 0.17 0.19 2.06 1.04 1.78
Aurkb Aurora kinase B 0.11 0.90 0.43 0.34 0.25 0.40
Ust5r Integral membrane transport protein 0.94 1.68 0.14 0.054 0.089 0.28
Upp1 Uridine phosphorylase 1 0.38 0.78 0.20 0.700 0.055 0.33
LOC500594 Ribosomal protein 0.20 0.63 0.78 0.20 0.55 0.48
Rbp1 Retinol-binding protein 1 0.48 0.62 0.19 0.58 0.36 0.63
Sycp2 Synaptonemal complex protein 0.18 0.25 0.24 0.048 0.69 0.28
Alb Albumin 0.17 2.90 2.67 0.46 2.52 2.54
Ifit3 Interferon-induced protein with tetratricopeptide repeats 3 0.82 0.88 0.50 0.88 0.083 0.37
Arl11 ADP-ribosylation factor-like 11 0.072 0.22 0.017 0.65 0.13 0.76
Scd1 Stearoyl-CoA desaturase-1 0.54 0.30 0.007 1.35 1.20 1.95
Mpeg1 Macrophage expressed gene 1 0.0023 0.54 0.94 0.44 0.17 0.40
Lrrc4c Leucine rich repeat containing 0.19 0.44 0.50 0.71 0.11 0.35
Sfrp5 Secreted frizzled-related protein 5 0.37 0.27 0.30 0.20 0.51 0.60
Cav1 Caveolin 0.39 0.18 0.62 0.75 0.07 0.63
Emr4 Member of the EGF-TM7 family 0.14 0.10 0.25 0.64 0.45 0.70
Dlx2 Distal-less homeobox 2 0.052 0.92 1.18 0.39 0.62 0.48
Nmu Neuromedin U 0.074 0.44 0.062 0.50 0.41 0.24
Cga Choriogonadotropin alpha 2.91 2.91 3.20 2.71 4.22 2.22
RNA sequencing was used to probe expression differences in brains in rats after 24 h of a single dose of analog. Expression data were analyzed
using a general linear model to generate differential expression profiles utilizing a likelihood ratio test of significance of all coefficients. RXR, reti-
noid X receptor.
ª 2015 Arizona State University. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
2015 | Vol. 3 | Iss. 2 | e00122
Page 15
P. A. Marshall et al. Rexinoids With Differential Side Effect Profiles
measures the active RXR-TR bound to the TRE that then
stimulates transcription of the luciferase reporter gene,
but the induction of luciferase is also influenced by the
available pool of coactivators. In support of this hypothe-
sis, we overexpressed the SRC-1 coactivator and observed
that the repressive effects of high-dose rexinoid treatment
were reversed (data not shown).
All of the analogs inhibit TSH synthesis to the same
extent in our rat model (Fig. 7), as opposed to the ana-
logs that inhibit TRE-mediated transcription differentially
in cell culture. TSH is synthesized in the pituitary gland,
and its promoter contains several regulatory regions,
including a negative regulatory element, suppressed by T3
binding to TR as well as RXR repression, shown to be
mediated by ligand (Haugen et al. 1997). This repression
in the pituitary is intriguingly regulated by RXRc (Hau-
gen et al. 1997), indicating perhaps that each analog can
bind RXRc with similar affinity. In contrast, HCT-116
cells contain endogenous RXRa and to a lesser extent
RXRb (van der Leede et al. 1993) and lack RXRc; Fig-
ure 4 hints that an RXRa/TR heterodimer is differentially
inhibited by different rexinoids, which have EC50s ranging
from 13 to 109 nmol/L (Table 1) (Wagner et al. 2009;
Furmick et al. 2012; Jurutka et al. 2013). Thus, we have
demonstrated that RXR ligands with different structures
can potentially mitigate some of the hypothyroid side
effects, at least in T3-TRE-responsive tissues.
Conclusion
Because of the wide-ranging applications of bexarotene
(1), not only in treating several human cancers but also
impacting pathways implicated in neurological disorders,
and the concomitant side effects of hypothyroidism and
raised triglycerides, we undertook an in vitro and in vivo
evaluation of five potent RXR-selective agonists (rexi-
noids) we reported recently (2, 4, 7, 9, and 14). Prior to
in vivo experiments, we tested all compounds, and bex-
arotene (1), for toxicity and mutagenicity in the Cyprotex
GreenScreen assay, whose results indicated that the com-
Figure 9. Differential expression analysis of rat brains after treatment with RXR agonists. RNA was isolated and expression determined using RNA
sequencing from rat brains after 24 h of a one time treatment with vehicle or compound. A likelihood ratio test of significance of all coefficients
demonstrated 200 genes that were detected to be differentially expressed at P < 1.0 9 103, fdr < 0.3 utilizing a general linear model of
expression comparison. RXR, retinoid X receptor.
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pounds were not expected to be more toxic than 1.
Indeed, this toxicity screen indicated that 9 was the least
toxic of all compounds. We had also screened several of
the novel rexinoids (Fig. 2) in cell-based TRE and SREBP
assays whose results suggested that many of the novel
rexinoids (Figs. 3–5) might show markedly different TSH
and lipid profiles in vivo. A rigorous examination of the
PK, TSH, cholesterol, HDL, LDL, and triglyceride profiles
in Sprague–Dawley rats for the five potent rexinoids (2,
4, 7, 9, and 14) in comparison to bexarotene (1) demon-
strates that while some features are similar among the
rexinoids and 1–such as the TSH profiles–other features,
such as the PK and triglyceride profiles, are significantly
different. In fact, compounds 4 and 9 had statistically
lower triglyceride levels at 24 h than 1, and 14 had a sta-
tistically much higher triglyceride level at 24 h than 1.
Additionally, we observed that compounds 7 and 9 had a
significantly higher Cmax than 1, whereas compound 2
had a much lower Cmax than 1. This difference in PK
profile compelled us to investigate factors that might
explain the difference between these compounds. Thus,
we examined the water solubility of the five rexinoids (2,
4, 7, 9, and 14) and 1 and we also modeled them to
arrive at calculated pKa values. The water solubility exper-
iments showed that the pyrimidine-ring containing com-
pounds (7 and 9) possessed two of the three highest
measured water solubilities, which might reasonably con-
tribute to their high observed Cmax values. Furthermore,
even though 2 possessed the second highest measured
water solubility, the pKa calculations suggested that 2 was
the most acidic which might also reasonably contribute to
its low observed Cmax value, despite its relatively good
solubility. Additionally, we extracted and sequenced RNA
from the brains of rats treated with bexarotene, novel
rexinoids (2, 4, 7, 9, and 14), and vehicle, and data from
these experiments indicated significant differences in
upregulation and repression of various genes between
analogs. Of particular note, compound 7 displayed the
greatest upregulation of genes across the table, and com-
pound 9 showed the greatest difference in upregulation
and repression of genes in comparison to bexarotene.
Taken together, these results suggest that several of the
five novel rexinoids–particularly, 4, 7, and 9–possess PK
and triglyceride profiles, as well as physical characteristics
that in comparison to 1 make them compelling candi-
dates for further preclinical studies.
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